133 related articles for article (PubMed ID: 31828591)
1. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
2. p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.
Heublein S; Page SK; Mayr D; Ditsch N; Jeschke U
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1163-70. PubMed ID: 26935926
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
[TBL] [Abstract][Full Text] [Related]
4. Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope.
Flechner A; Butschak G; Löffler A; Rühmann J; Nishimura SI; Dölling R; Purfürst B; Goletz S; Danielczyk A; Karsten U
Int Immunopharmacol; 2019 Jul; 72():186-194. PubMed ID: 30999209
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of the human tumor-specific antigen structure Galβ1-3GalNAcα- (Thomsen-Friedenreich) and related structures on gut bacteria: prevalence, immunochemical analysis and structural confirmation.
Henderson G; Ulsemer P; Schöber U; Löffler A; Alpert CA; Zimmermann-Kordmann M; Reutter W; Karsten U; Goletz S; Blaut M
Glycobiology; 2011 Oct; 21(10):1277-89. PubMed ID: 21551457
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
[TBL] [Abstract][Full Text] [Related]
8. Expression of mucin-associated carbohydrate core antigens in esophageal squamous cell carcinomas.
Flucke U; Zirbes TK; Schröder W; Mönig SP; Koch V; Schmitz K; Thiele J; Dienes HP; Hölscher AH; Baldus SE
Anticancer Res; 2001; 21(3C):2189-93. PubMed ID: 11501845
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms.
Baldus SE; Hanisch FG; Kotlarek GM; Zirbes TK; Thiele J; Isenberg J; Karsten UR; Devine PL; Dienes HP
Cancer; 1998 Mar; 82(6):1019-27. PubMed ID: 9506345
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro.
Jeschke U; Richter DU; Hammer A; Briese V; Friese K; Karsten U
Histochem Cell Biol; 2002 Mar; 117(3):219-26. PubMed ID: 11914919
[TBL] [Abstract][Full Text] [Related]
13. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
14. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
15. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
[TBL] [Abstract][Full Text] [Related]
16. Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas.
Zhan XX; Zhao B; Diao C; Cao Y; Cheng RC
Endocr Pathol; 2015 Mar; 26(1):21-6. PubMed ID: 25614211
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: A clinicopathologic study of 264 patients.
Baldus SE; Zirbes TK; Hanisch FG; Kunze D; Shafizadeh ST; Nolden S; Mönig SP; Schneider PM; Karsten U; Thiele J; Hölscher AH; Dienes HP
Cancer; 2000 Apr; 88(7):1536-43. PubMed ID: 10738210
[TBL] [Abstract][Full Text] [Related]
18. Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176).
Andergassen U; Kölbl AC; Zebisch M; Heublein S; Hutter S; Ilmer M; Schindlbeck C; Friese K; Jeschke U
Histol Histopathol; 2014 Jul; 29(7):913-23. PubMed ID: 24399516
[TBL] [Abstract][Full Text] [Related]
19. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
Kurtenkov O; Izotova J; Klaamas K; Sergeyev B
Biomed Res Int; 2014; 2014():830847. PubMed ID: 25276822
[TBL] [Abstract][Full Text] [Related]
20. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
